Specialties

General

Trial will inform choice between mAbs in severe asthma

By Michael Woodhead

12 Feb 2019

Share:

Respiratory physicians in NSW are seeking research collaborators to take part in a head to head trial of mepolizumab and omalizumab in patients with severe allergic and eosinophilic asthma. Professor Peter Wark, a senior respiratory specialist at John Hunter Hospital and the University of Newcastle, is hoping to recruit 160 patient across Australia and New ...

Already a member?

Enter your email to keep reading.

OR

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.